Your Location:Home >News >DRUG NEWS OF OLAPARIB



AstraZeneca and Merck & Co report Phase III data for ovarian cancer.

On 28 September 2019 AstraZeneca and Merck & Co reported data from the PAOLA-1 phase III trial evalua-ting olaparib (LYNPARZA) when added to bevacizumab (a humanized anti-VEGF antibody) for the first-line maintenance treatment of patients with newly-diagnosed advanced ovarian cancer who had a complete or partial response to first-line treatment with platinum-based chemotherapy and bevacizumab. In the overall patient population, treatment with olaparib plus bevacizumab resulted in a significant reduction in the risk of disease progression or death by 41% compared with bevacizumab alone. The median progression-free survival (PFS) was 22.1 and 16.6 months for the olaparib plus bevacizumab and bevacizumab alone arms, respectively (p less than 0.0001). In a subgroup analysis of BRCA-mutation positive patients, the median PFS was 37.2 months for olaparib plus bevacizumab compared with 21.7 months for bevacizumab alone. Olaparib, an oral poly ADP-ribose polymerase (PARP) inhibitor, is available in the USA, the EU, Japan, Canada, Australia and Mexico for the treatment of BRCA-mutated ovarian cancer. The agent is also available in the USA and Japan and is approved in the EU for breast cancer.